In conclusion, we suggest that the mechanism behind GP‐2250's anti‐neoplastic effect on ovarian cancer cells includes inhibition of glycolysis via modulation of HK2 activation and expression and inhibition of HIF‐1α induced VEGF secretion. Here, VEGFA is linked to ovarian carcinoma.